Acute Respiratory Distress Syndrome – Epidemiology – Mature Markets

Clarivate Epidemiology’s coverage of acute respiratory distress syndrome (ARDS) comprises epidemiological estimates of key patient populations in the major mature pharmaceutical markets (the United States, France, Germany, Italy, Spain, the United Kingdom, and Japan). We report the incidence of ARDS for each country, as well as annualized case counts projected to the national population.

Most patient populations are forecast over a period of 20 years for the major mature pharmaceutical markets.

Clarivate Epidemiology’s ARDS forecast will answer the following question:

  • How will demographic trends, such as population aging and improving life expectancy, affect the epidemiology of ARDS over the forecast period?

All forecast data are available on the Clarivate Insights Platform in tabular format, with options to download to Excel. All populations are accompanied by a comprehensive description of the methods and data sources used, with hyperlinks to external sources. A summary evidence table generated as part of our systematic review of the epidemiological literature is also provided for full transparency into research and methods.

Clarivate Epidemiology forecasts the following four ARDS patient populations:

  • Diagnosed events.
  • Diagnosed events by severity.
  • Diagnosed events by type of pulmonary injury.
  • Diagnosed events of sepsis-related versus non-sepsis-related ARDS.

Note: Coverage may vary by country.

launch Related Market Assessment Reports